Late-stage clinical firm, Prothena Corporation plc, is aiming to combat diseases that result from protein dysregulation in the United States, with a focus on novel therapy development. Currently, the company is working on several promising treatments, including the investigational humanized antibody Birtamimab. This drug is currently in Phase III clinical trials concerning its potential to treat abnormal protein build-up that causes amyloidosis in AL instances. Meanwhile, the company's humanized monoclonal antibody, Prasinezumab, is also showing promise, with the drug in Phase IIb clinical trials to treat Parkinson's and other related synucleinopathies. Prothena Corporation plc is also continuing development on NNC6019, which completed Phase I clinical trials with the goal of treating ATTR amyloidosis, and PRX005, which is currently going through Phase I clinical trials aimed at treating Alzheimer's disease. The company's discovery and preclinical programs show significant potential for developing treatments for Alzheimer's and other neurodegenerative diseases. These programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine aimed at treating and preventing Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has several collaboration agreements in place to help bring these therapies to market. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. regarding antibodies that target alpha-synuclein, including prasinezumab, as well as a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is headquartered in Dublin, Ireland.
Prothena Corp's ticker is PRTA
The company's shares trade on the NASDAQ stock exchange
They are based in Dublin, Ireland
There are 51-200 employees working at Prothena Corp
It is http://www.prothena.com
Prothena Corp is in the Healthcare sector
Prothena Corp is in the Biotechnology industry
The following five companies are Prothena Corp's industry peers: